Exelixis
EXEL
#1360
Rank
โ‚น1.561 T
Marketcap
โ‚น6,300
Share price
-0.12%
Change (1 day)
80.86%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): โ‚น302.96

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น314.06. In 2025 the company made an earnings per share (EPS) of โ‚น275.04.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)โ‚น302.9610.15%
2025โ‚น275.04
2023โ‚น62.1714.61%
2022โ‚น54.25-22.97%
2021โ‚น70.43100%
2020โ‚น35.21-65.09%
2019โ‚น100.88-53.91%
2018โ‚น218.89333.96%
2017โ‚น50.44-260.61%
2016-โ‚น31.41-58.75%
2015-โ‚น76.14-42.45%
2014-โ‚น132.295.3%
2013-โ‚น125.62

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
โ‚น831.19 164.66%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น72.33-76.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น1,544 391.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚น181.10-42.34%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น120.44-61.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น432.07 37.58%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚น304.32-3.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-โ‚น1,353-530.91%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚น79.94-125.45%๐Ÿ‡บ๐Ÿ‡ธ USA